Related Experiment Video
Updated: Dec 27, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.7K
Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and
Meng Xu1, Yuan Yuan2, Peijing Yan3
1General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China; Ning Xia Medical University Graduate School, YinChuan, China.
Clinical Breast Cancer
|March 7, 2020
Summary
Androgen receptor (AR) expression is not linked to patient survival in triple-negative breast cancer (TNBC). This meta-analysis found no significant association between AR status and outcomes like disease-free or overall survival in TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Androgen receptor (AR) is a potential biomarker in breast cancer.
- The prognostic value of AR in triple-negative breast cancer (TNBC) is debated.
Purpose of the Study:
- To investigate the association between AR expression and survival outcomes in TNBC patients through a meta-analysis.
Main Methods:
- Searched PubMed, Embase, Cochrane Library for studies on AR expression and TNBC prognosis (1946-May 2019).
- Pooled hazard ratios (HR) and confidence intervals (CI) for survival endpoints using fixed- or random-effect models.
- Included 27 studies with 4914 TNBC patients.
Main Results:
- AR was expressed in 27.96% of TNBC patients.
- AR expression showed no significant association with disease-free survival (HR 0.923; P=0.634).
- AR expression was not linked to overall survival (HR 0.910; P=0.531), distant disease-free survival (HR 1.02; P=0.489), or recurrence-free survival (HR 0.957; P=0.906).
Conclusions:
- AR expression is not associated with prognosis in triple-negative breast cancer.
- Findings suggest AR is not a reliable prognostic biomarker for TNBC survival outcomes.
